Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02015637 · ClinicalTrials.gov registry record · Phase 3
Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea
A Phase 3 study, sponsored by Melinta Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT02015637 is a Phase 3 study that was terminated before completion, run by Melinta Therapeutics. The registered enrollment target is 460 participants.
The verdict
NCT02015637, a Phase 3 study, was terminated before completion, sponsored by Melinta Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of a single oral dose of delafloxacin versus a single intramuscular injection of ceftriaxone in subjects with uncomplicated cervical, urethral, rectal, or pharyngeal gonorrhea.
Interventions
- DRUG Ceftriaxone
- DRUG Delafloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2014-01-23 |
| Est. Completion | 2014-12-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02015637
The ClinicalTrials.gov registry entry for NCT02015637 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ceftriaxone is the first listed.
NCT02015637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02015637 about?
NCT02015637 is a clinical study titled "Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea". The purpose of this study is to evaluate the effects of a single oral dose of delafloxacin versus a single intramuscular injection of ceftriaxone in subjects with uncomplicated cervical, urethral, rectal, or pharyngeal gonorrhea.
What is the current status of trial NCT02015637?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2014-01-23. Estimated completion is 2014-12-10.
What interventions are being tested in trial NCT02015637?
The interventions under investigation include: Ceftriaxone (DRUG), Delafloxacin (DRUG).
Who is sponsoring clinical trial NCT02015637?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.